Get the Stockscreener App
277.16
1.20%
3.17
After Hours:
280.16
3.00
+1.08%
Alnylam Pharmaceuticals Inc stock is traded at $277.16, with a volume of 547.63K.
It is up +1.20% in the last 24 hours and up +17.48% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$273.99
Open:
$274.86
24h Volume:
547.63K
Relative Volume:
0.77
Market Cap:
$35.95B
Revenue:
$2.09B
Net Income/Loss:
$-332.26M
P/E Ratio:
-105.79
EPS:
-2.62
Net Cash Flow:
$16.06M
1W Performance:
+0.63%
1M Performance:
+17.48%
6M Performance:
+18.59%
1Y Performance:
+53.94%
1-Day Range:
$269.00
$279.36
1-Week Range:
$269.00
$287.22
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam's Crucial 2024 Financial Results Coming: Key Date for Biotech Investors - StockTitan
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Baader Bank Aktiengesellschaft Has $905,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Forsta AP Fonden Buys 3,900 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
SteelPeak Wealth LLC Has $819,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - Investing.com
Zacks Research Issues Positive Estimate for ALNY Earnings - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity - MSN
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity By Investing.com - Investing.com South Africa
New Strong Buy Stocks for January 27th - MSN
Hypertension Clinical and Non-Clinical Studies, Key - openPR
Brighton Jones LLC Buys New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Boosted by Nisa Investment Advisors LLC - MarketBeat
Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells $3,093,750.00 in Stock - MarketBeat
Alnylam Pharmaceuticals director sharp sells $3.09 million in stock By Investing.com - Investing.com Australia
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock - MSN
Alnylam Pharmaceuticals director sharp sells $3.09 million in stock - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
When the Price of (ALNY) Talks, People Listen - Stock Traders Daily
Alnylam Pharmaceuticals receives a prestigious "Tell Award" for business investment in Switzerland - StreetInsider.com
Hemophilia Clinical and Non-Clinical Studies, Key Companies, - openPR
FY2024 Earnings Estimate for ALNY Issued By Leerink Partnrs - MarketBeat
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors - BioPharma Dive
Merit Financial Group LLC Invests $587,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Traynor Capital Management Inc. Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals - MSN
Perpetual Ltd Purchases 4,819 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? - MSN
Assenagon Asset Management S.A. Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Hemophilia B Market to Show Remarkable Growth Trends from 2024 - openPR
Gateway Investment Advisers LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 6.7%Here's What Happened - MarketBeat
Empirical Asset Management LLC Takes $12.15 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
FY2024 Earnings Forecast for ALNY Issued By Zacks Research - MarketBeat
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment? - Simply Wall St
Burney Co. Buys 4,791 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
What is William Blair's Estimate for ALNY FY2024 Earnings? - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters ATTR-CM stock outlook - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Up 7.1%Still a Buy? - MarketBeat
Alnylam Shares Rise 8% On Preliminary Product Revenue Growth - MarketWatch
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Alnylam shares jump on strong revenue forecast and profit outlook By Investing.com - Investing.com Australia
Alnylam shares jump on strong revenue forecast and profit outlook - Investing.com
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Alnylam sees 2024 net product revenues of over $1.6B, up 33% Y/Y (NASDAQ:ALNY) - Seeking Alpha
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Jan 27 '25 |
Sale |
285.00 |
52,592 |
14,988,720 |
11,989 |
1.64%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):